glp-1 bone loss Use Associated with Lower Osteoporosis Risk in Adults with Type 2 Diabetes but Higher Risk in Adults Without Diabetes GLP-1s and bone loss!

labels warn of vision changes without naming NAION

pharma market

Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT)

(13) Additionally, GLP-1 signaling may help suppress pro-inflammatory pathways, reducing the chronic low-grade inflammation associated with both obesity and bone loss

It should be noted that while GLP-1 agonists positively impact metabolism upstream of the liver, this may not subsequently improve the fibrotic liver injury within the tested treatment duration

Similarly, compared with lixisenatide, dulaglutide, liraglutide, exenatide once-weekly, and albiglutide decreased HbA1c by 0.66%, 0.60%, 0.53%, and 0.39%, respectively [63]